AngioDynamics Inc. (ANGO) announced the U.S. Food and Drug Administration has granted 510(k) clearance for its BioFlo peripherally inserted central catheters or PICCs with Endexo technology designed to reduce the accumulation of catheter-related thrombus on, and in, the catheter.
It is expected to launch in the second quarter of fiscal year 2013. These products are currently CE marked for Europe and are approved in Canada and other international markets.
"We expect to launch BioFlo technology with PASV PICCs in the U.S. within the next 30 days," said Chuck Greiner, Vice President of the Global Vascular Access Franchise.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org